The pharmacologic era of retinal therapy is here to stay, and justifiably so, as its triumphs have transformed age-related macular degeneration treatment. Translational research in retinal cell biology and pharmacology continues to bring new retinal therapeutic applications from the research bench to the patient bedside, but as Schachat1 has observed, translational research II is essential to define optimal application to clinical practice. Perhaps the pharmacologic era could be thought of as being in its adolescence, as the virtual explosion of case series and basic science ideas has left the clinician with a confusing array of options largely applied by anecdotal experience. Maturation will require more randomized controlled clinical trials to achieve widespread clinical acceptance of treatment strategies.
Smiddy WE. Intravitreal Corticosteroids for Diabetic Retinopathy Prevention. Arch Ophthalmol. 2009;127(12):1672-1673. doi:10.1001/archophthalmol.2009.336